Inventiva présentera lors de la session « late-breaker » de l'AASLD The Liver Meeting®, les résultats de l'analyse finale de la Phase 2 évaluant la combinaison de lanifibranor avec empagliflozine chez des patients atteints de MASH et DT2
15 nov. 2024 16h00 HE
|
INVENTIVA
Les résultats seront présentés lundi 18 novembre par poster lors de la session « late-breaker » du congrès de l’AASLD The Liver Meeting® à San Diego.L'étude LEGEND a atteint son critère principal...
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
15 nov. 2024 16h00 HE
|
INVENTIVA
Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its...
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
11 nov. 2024 08h00 HE
|
Hepion Pharmaceuticals, Inc.
KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product...
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
06 nov. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor...
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
31 oct. 2024 07h00 HE
|
Madrigal Pharmaceuticals, Inc.
Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered...
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
30 oct. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
21 oct. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to...
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
18 oct. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31,...
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
02 oct. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual...
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
01 oct. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...